CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,950 enrolled
Drug / intervention
WomECother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06192017
NCT06192017N/ACompleted

Development of a Molecular Diagnostic Tool for Endometrial Cancer.

MiMARK Diagnostics, S.L.·observational·Posted Jan 5, 2024·Updated Aug 28, 2025

In Brief

An observational study evaluating WomEC for Endometrium Cancer. Completed, enrolled 1,950 participants across 26 sites.

Detailed Summary

WomEC is an in vitro diagnostic test for Endometrial Cancer (EC) based on the detection of the expression level of a combination of 5 proteins in the soluble fraction of a pipelle biopsy specimen. The aim of the study consists in validating WomEC's ELISA test, creating and freezing an algorithm to rule out EC in post-menopausal women with abnormal uterine bleeding (AUB).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

N/ACompletedFinished
202420252026
First PostedJan 5, 2024
Enrollment StartOct 18, 2023
Primary CompletionJul 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.5 years ago

Interventions

WomECother

The study will collect pipelle biopsies from post-menopausal women presenting with AUB entering to the EC diagnostic process at the clinical consultancy or emergency room. In the study an endometrial biopsy by aspiration will be collected (i.e., pipelle biopsy) and it will be used for (1) diagnostic purposes following current procedures (i.e., pathological examination and diagnosis); (2) placed in a collection tube for WomEC test.